194 related articles for article (PubMed ID: 15875221)
21. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Braybrooke JP; Slade A; Deplanque G; Harrop R; Madhusudan S; Forster MD; Gibson R; Makris A; Talbot DC; Steiner J; White L; Kan O; Naylor S; Carroll MW; Kingsman SM; Harris AL
Clin Cancer Res; 2005 Feb; 11(4):1512-20. PubMed ID: 15746054
[TBL] [Abstract][Full Text] [Related]
22. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2005 Apr; 313(1):154-64. PubMed ID: 15608076
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of naringin on the micronuclei induced by ifosfamide in mouse, and evaluation of its modulatory effect on the Cyp3a subfamily.
Alvarez-González I; Madrigal-Bujaidar E; Dorado V; Espinosa-Aguirre JJ
Mutat Res; 2001 Sep; 480-481():171-8. PubMed ID: 11506811
[TBL] [Abstract][Full Text] [Related]
24. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
25. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
26. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
27. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
28. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
29. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
30. Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level.
Sarikaya D; Bilgen C; Kamataki T; Topcu Z
Biopharm Drug Dispos; 2006 Nov; 27(8):353-9. PubMed ID: 16894644
[TBL] [Abstract][Full Text] [Related]
31. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
Yanagihara Y; Kariya S; Ohtani M; Uchino K; Aoyama T; Yamamura Y; Iga T
Drug Metab Dispos; 2001 Jun; 29(6):887-90. PubMed ID: 11353758
[TBL] [Abstract][Full Text] [Related]
32. Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking.
Bathelt C; Schmid RD; Pleiss J
J Mol Model; 2002 Nov; 8(11):327-35. PubMed ID: 12483228
[TBL] [Abstract][Full Text] [Related]
33. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
34. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Di Marco MP; Wainer IW; Granvil CL; Batist G; Ducharme MP
Pharm Res; 2000 Jun; 17(6):645-52. PubMed ID: 10955835
[TBL] [Abstract][Full Text] [Related]
35. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
Tychopoulos M; Corcos L; Genne P; Beaune P; de Waziers I
Cancer Gene Ther; 2005 May; 12(5):497-508. PubMed ID: 15746946
[TBL] [Abstract][Full Text] [Related]
36. Measurement of in vitro cytochrome P450 2B6 activity.
Walsky RL; Obach RS
Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
[TBL] [Abstract][Full Text] [Related]
37. Human CYP2B6: expression, inducibility and catalytic activities.
Gervot L; Rochat B; Gautier JC; Bohnenstengel F; Kroemer H; de Berardinis V; Martin H; Beaune P; de Waziers I
Pharmacogenetics; 1999 Jun; 9(3):295-306. PubMed ID: 10471061
[TBL] [Abstract][Full Text] [Related]
38. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
39. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
[TBL] [Abstract][Full Text] [Related]
40. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
